Abstract:649 Background: The outcomes after the treatment for pancreatic ductal adenocarcinoma (PDAC) are generally disappointing. Except for MSI high tumors, PDAC is considered to be resistant to immune checkpoint inhibitors (ICI). Radiotherapy is thought to be a potential option to foster the effect of ICI. This investigator-initiated trial evaluated safety and efficacy of combining stereotactic radiotherapy (SRT) and ICI. Methods: In this open-label, multicenter phase 1/2 study, patients (pts) aged ≥ 18 years with histologically confirmed locally advanced unresectable PDAC with no distant metastases were enrolled after initial four cycles of induction chemotherapy with FOLFIRINOX. The experimental treatment consisted of SRT (32 Gy in 4 fractions/4 weeks) and sequential nivolumab (N) therapy (3mg/kg every two weeks) administered until disease progression or unacceptable toxicity. After N discontinuation pts could continue treatment with standard chemotherapy regimens. The primary end point was safety (events graded according to NCI CTCAE 4.03 criteria). The secondary objectives were progression free survival (PFS), overall survival (OS), evaluation of selected biomarkers, and quality of life (QoL; EORTC QLQ-C30 questionnaire). The PFS and OS were defined as the time from enrollment to event (i.e., did not include 3-month of ICT and screening). Results: A total of 22 pts. were screened, and 15 pts. were enrolled. Median age was 58 (range 38-74) years, and 53 % were males. All tumors were microsatellite (MS) stable or had unknown MS status. All patients underwent SRT according to the study protocol and all started N. The median number of N cycles was 11 (range 2-17). The toxicity of SRT was low and non-significant. The toxicity of N therapy was expectable. No Grade 4-5 toxicity was observed. Three pts. discontinued therapy because of toxicity (liver test elevation in two cases and unmanageable arthralgia). Median PFS and OS were 8.1 and 13.0 months, resp.; 12-month PFS and OS were 0 % and 66.7%, resp.; and 24-month OS was 8.9 %. The level of selected biomarkers correlated with clinical or radiological disease control. The QoL assessed by pts during the therapy was acceptable, deterioration of QoL in most cases occurred with tumor progression. Conclusions: The toxicity of SRT and N therapy was low and acceptable. There was no unexpected toxicity of combination of SRT of PDAC primary tumor and N, but this regimen did not lead to any long-term treatment responses. Trial registration: EudraCT: 2017-003404-52; ClinicalTrials.gov: NCT04098432. The study was financially supported by Bristol-Meyer-Squibb. Clinical trial information: NCT04098432 .

Anti-Pd-1 Therapy Combined With Chemotherapy In Patients With Advanced Pancreas Cancer In A Real-World Clinical Setting.

Immune Checkpoint Inhibitors Combined with Chemotherapy for the Treatment of Advanced Pancreatic Cancer Patients

PD-1 Blockade Combined with Gemcitabine Plus Nab-Paclitaxel is Superior to Chemotherapy Alone in the Management of Unresectable Stage III/IV Pancreatic Cancer: a Retrospective Real-World Study.

Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study

A Retrospective Cohort Study Of Anti-Pd-1 Therapy Combined With Chemotherapy In Patients With Advanced Biliary Tract Cancer.

Clinical Observation of Immune Checkpoint Inhibitors in the Treatment of Advanced Pancreatic Cancer: a Real-World Study in Chinese Cohort.

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

A Real-World Study of the Efficacy and Safety of Anti-Programmed Cell Death-1 Therapy Combined with Chemotherapy or Targeted Therapy in Patients with Advanced Biliary Tract Cancer.

Real-world evaluation of AG plus PD-1 antibody in old patients with advanced unresectable pancreatic cancer.

Efficacy and Safety of Immune Checkpoint Inhibitors in Advanced Pancreatic Cancer: A Real World Study in Chinese Cohort

Anti-PD-1 Therapy Combined with Chemotherapy or Target Therapy in Patients with Advanced Biliary Tract Cancer in Real-World Clinical Setting

Stereotactic radiotherapy plus anti PD-1 therapy in patients with locally advanced unresectable pancreatic cancer: Results from a phase 1/2 clinical trial (CA209-9KH).

Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer

Efficacy And Safety Of Pd-1 Inhibitors In Combination With Chemotherapy Versus Chemotherapy As First And Second Line Treatment In Advanced Gastric And Gastroesophageal Junction Cancer: Preliminary Data From A Real-World Setting.

PD-1 Blockade Plus Chemotherapy Followed by Concurrent SBRT with SIB As Preoperative Therapy for Patients with Potentially Resectable Pancreatic Cancer: A Single-Arm Phase 2 Study.

Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial